Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis

Figure 1 The flow diagram depicting the preferred reporting items for systematic reviews and meta-analyses in study selection.

Figure 2 Meta-analysis of the biochemical responses in only chronic hepatitis B patients and in chronic hepatitis B with nonalcoholic fatty liver disease patients. A: Biochemical response in only chronic hepatitis B (CHB) patients and in CHB with nonalcoholic fatty liver disease (NAFLD) patients until 48 wk; B: Biochemical response in only CHB patients and in CHB with NAFLD patients until 96 wk.

Figure 3 Meta-analysis of virological response in only chronic hepatitis B patients and in chronic hepatitis B with nonalcoholic fatty liver disease patients. A: Virological response in only chronic hepatitis B (CHB) patients and in CHB with nonalcoholic fatty liver disease (NAFLD) patients until 48 wk; B: Virological response in only CHB patients and in CHB with NAFLD patients until 96 wk; C: Subgroup analysis according to the treatment regimens until 48 wk; D: Subgroup analysis according to the treatment regimens until 96 wk.

Figure 4 Meta-analysis of the serological responses in only chronic hepatitis B patients and in chronic hepatitis B with nonalcoholic fatty liver disease patients. A: Serological response in only chronic hepatitis B (CHB) patients and in CHB with nonalcoholic fatty liver disease (NAFLD) patients until 48 wk; B: Serological response in only CHB patients and in CHB with NAFLD patients until 96 wk.

Figure 5 Meta-analysis of the incidence of hepatocellular carcinoma in only chronic hepatitis B patients and in chronic hepatitis B with nonalcoholic fatty liver disease patients.